REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Cyclopentanohydrophenanthrene Ring System Doai > Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System > Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring SystemOxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010504 - Polymorphic and amorphous salt forms of squalamine dilactate The invention relates to select squalamine salts, methods of their synthesis, their therapeutic use and their advantages relating to manufacturing, product stability and toxicity. More specifically, this application is directed to various forms of the dilactate salt of squalamine and their utility in inhibiting neovascularization and endothelial cell proliferation. ... 12/14/06 - 20060281724 - Methods for treating shock The invention relates to methods of treating shock in a subject by administering a pharmaceutically effective amount of androstenetriol (AET), androstenediol (AED) or derivatives thereof to a subject suffering from or exhibiting the symptoms of shock. In one particular embodiment, the subject is suffering from hemorrhagic shock. The invention also ... 11/30/06 - 20060270645 - Agents and methods for enhancing bone formation The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and method to treat patients to maintain bone mass, enhance bone formation and/or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents known ... 11/02/06 - 20060247220 - Preventing the crystallization of cholesterol using oxysterols A therapeutic agent in the treatment of humans or animals wherein the agent is oxysterol, and a method of treatment wherein the agent is administered orally, parenterally, transdermally, buccally, sublingually or otherwise to deliver a sufficient amount of oxysterol to the human or animal to prevent or delay plaque formation ... 10/26/06 - 20060241093 - Use of dhea derivatives for enhancing physical performance A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells. ... 09/28/06 - 20060217359 - Therapeutic procedures As illustrated herein, cholesterol is oxidized when it is present in atherosclerotic plaques. This reaction generates cytotoxic cholesterol oxidation or ozonation products. The present application is directed to the products of cholesterol ozonation, binding entities directed against such products, and methods of using such binding entities and cytotoxins to treat ... 09/21/06 - 20060211667 - Use of pregnane steroid derivatives for enhancing physical performance wherein R1=H and R2=H, or R1 and R2 combined form a single bond; R3 is one of OH and O; R5 is one of an α-hydrogen and a β-hydrogen; R6 is one of α-methyl and H; R7 is one of α-methyl and H; R17 is one of H and OH; ... 08/10/06 - 20060178354 - Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof The invention relates to the treatment of chronic pain using DHEA or derivatives thereof either alone or in combination with at least one other drug. The invention also includes compositions comprising DHEA or a derivative thereof and a second drug. ... 07/27/06 - 20060166956 - Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration. ... 06/22/06 - 20060135499 - Method of achieving accelerated weight loss by administration of a weight loss accelerating agent to a dieting mammal Accelerating weight loss by admtinistering to a dieting mammal the weight loss accelerating agent 7-oxo DHEA or a pro-drug thereof incapable of in vivo conversion to testosterone. ... 06/08/06 - 20060122161 - Methods for treating or preventing cancer by preventing, inhibiting, or arresting cell cycling when X is S, Y is ═O, Z is ═O, and R is hydrocarbyl or N(R1)(R2), wherein each of R1 and R2 is independently selected from H or a hydrocarbyl group. ... 04/27/06 - 20060089340 - Novel steroids and steroid mimetics; method for their production; and use thereof The invention relates to the production and use of novel 14β-alkyl-18-norsteroids, 8α,14β-dialkyl-18-norsteroids, spiro[cyclopentano-perhydronaphthalin]-3,1′-pentanes or hexanes in addition to 14β-fluoro-15β,17β-dihydroxy-steroids, by reacting 17-hydroxy-14,15-epoxi-steroids with water-free acids or Lewis acids and followed by derivatisation. The resulting compounds can be used as intermediate products for or as medicaments in human and veterinary medicine, ... 04/13/06 - 20060079492 - Compositions and treatment methods The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method. ... 03/30/06 - 20060069076 - Lxr/rxr-related methods and compositions This invention provides methods for decreasing the amount of Aβ peptide produced by a neuronal cell comprising contacting the cell with an agent that, when in contact with the neuronal cell, causes activation of the cell's Liver X Receptor (LXR) and/or Retinoid X Receptor (RXR). This invention also provides for ... 03/09/06 - 20060052353 - Topical dermatological formulations and use thereof A topical formulation of an androstane steroid compound of improved solubility in combinations of the solvents propylene glycol and propylene carbonate. ... 01/12/06 - 20060009434 - New 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17beta-hydroxy steroid dehydrogenase type 1 R7 and R8 in each case mean a hydrogen atom or together a CH2 group, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by the inhibition of 17β-hydroxy steroid dehydrogenase type 1. ... 01/12/06 - 20060009433 - Neuroprotective spirostenol pharmaceutical compositions The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a disorder or disease related to, or the symptoms associated with a neurodegenerative disorder such as neurotoxicity or a neuropathology in a subject, particularly to beta-amyloid-induced neurotoxicity and Alzheimer's disease. The ... 01/05/06 - 20060003977 - Tibolone-adsorbates The present invention relates to a process for the preparation of powders containing active ingredients in which amorphous tibolone is present in a morphologically stable form, where one starts with a solution of tibolone in at least one organic solvent where the total water content of the solvent is not ... 11/17/05 - 20050256095 - Asthma and colitis treatment methods The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of ... 11/03/05 - 20050245496 - High-purity composition comprising (7a,17a)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one and a process for purifying (7a,17a)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one The invention pertains to a process for the preparation of a high-purity composition of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one. The process provides for a composition with less than 0.5% of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one. This composition can be used as a source for the preparation of stable pharmaceutical dosage units. ... 09/15/05 - 20050203074 - Modified aromatase inhibitors having improved bioavailability The present invention relates to the modification of 3-beta-hydroxyandrost-4-ene-6,17-dione (“3-OHAT”) and its metabolites/derivatives at either the 3rd or 17th carbon or 3rd and 17th carbons with various ethers and/or esters and to the modification of 3-beta-hydroxyandrost-4-ene-6,17-dione (“3-OHAT”) and its metabolites/derivatives at carbon 6 with a methyl, methoxy, methylene, hydroxymethylene or ... 09/01/05 - 20050192263 - Novel 17beta-hydroxysteroid dehydrogenase type i inhibitors 3,15-substituted estrone compounds which act as inhibitors of 17β-hydroxysteroid dehydrogenase type I (17β-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases ... 08/18/05 - 20050182039 - Use of loteprednol etabonate for the treatment of dry eye Disclosed in embodiments herein is a method of treating dry eye in a patient in need thereof, the method comprising topically administering to the patient Loteprednol etabonate in an ophthalmolically acceptable carrier. ... 07/14/05 - 20050153949 - Testosterone derivative The invention is the novel androgen (7α,17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr-4en-3one (MENT undecanoate). This compound distinguishes favourably from other testosterone derivatives in that it has a good solubility in oily media. It particularly exhibits a good dissolved potency relative to testosterone. The compound is particularly suitable for administration by means of injection. ... 06/23/05 - 20050137178 - Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol and compounds converted in vivo to one of the foregoing presursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment ... ### FreshPatents.com Support |